Navigation Links
ExonHit Therapeutics - 2007 Financial Results
Date:3/5/2008

2007 (EUR 5.0 million in 2006);

- Net loss of EUR 7.3 million, against EUR 4.5 million in 2006; - Cash burn from operations remained limited at EUR 4.9 million (EUR 3.9 million in 2006);

- Consolidated cash and cash equivalents position increased to EUR 31.3 million at December 31, 2007 by issuance of new shares against EUR 24.0 million at December 31, 2006.

- Strategic progress in therapeutics

- New financial commitments from Allergan on the collaboration with the nomination in regulatory pre-development of a second compound resulting from the collaboration.

- Strengthened position in diagnostics

- Initiation of a new program in the field of blood diagnostic of prostate cancers in the framework of the collaboration signed with bioMerieux. To this end, ExonHit has initiated to the financing of clinical trials in Austria to speed the collection of blood samples.

- Development of the SpliceArray(TM) business

- Implementation and certification of an Affymetrix platform to equip a second service laboratory in Paris.

- Strengthened patent portfolio

- 10 new patents were filed in 2007, bringing the total of active patents filed since the Company's creation in 1997 to 177. 26 patents have been granted to ExonHit Therapeutics since its inception.

Bruno Tocque, President of the Management Board of ExonHit, commented: "We have reached our main objectives in 2007. We are very proud of the work accomplished by our collaborators in a context of market agitation which has been very disturbing for companies like ExonHit which invest in innovation with 65% of its operating expenses devoted to R&D.

We have kept our cash burn from operations below EUR 5 million while still investing more in R&D than in 2006. At December 31, 2007, we have an enviable cash and cash equivalent position of EUR 31.3 million. We will thereby have the capacity to continue our investment efforts, and notably in Alzheimer's
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Quantum computers have yet to materialise. Yet, scientists ... making such computers faster. One such approach relies ... controlled by applying an electric field. A new ... coherently coupled quantum dots (TQDs) with electrical impulses ... for example, should TQDs be used as quantum ...
(Date:7/24/2014)... most natural and synthetic processes prefer to settle ... or energyit is within the realm of non-equilibrium ... constant changes in energy and phases, such as ... conditions allow humans to regulate their body temperature, ... with seismic activity. , But even though ...
(Date:7/24/2014)... Research and Markets has announced ... Analytical Instruments Market 2014-2018" report to their offering. ... Genomics is the study of the gene and its ... and functions of proteomes or sets of proteins by ... involves the mapping of genes and DNA sequencing to ...
(Date:7/24/2014)... July 24, 2014 SRI International has been ... National Institute of Allergy and Infectious Diseases (NIAID), part ... development of potential therapies for HIV infection and AIDS. ... HIV and AIDS and the complications and opportunistic infections ... preventing sexual transmission of HIV. According ...
Breaking Biology Technology:New approach to form non-equilibrium structures 2Global Genomics and Proteomics Analytical Instruments Market 2014-2018: Key Vendors are Agilent, Bio-Rad , F. Hoffmann, La Roche, Illumina, PerkinElmer and Thermo Fisher Scientific 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 2National Institute of Allergy and Infectious Diseases Awards SRI International Contract to Study New Therapies for HIV and AIDS 3
... Richard P. Jones II named Vice President and General Manager ... dispense up to one million prescriptions a week, FRANKLIN ... MHS ), one of the nation,s leading pharmacy benefit,managers, today ... home of world,s largest and most-advanced automated pharmacy,capping a nearly ...
... SYK ) announced that it will host a ... Eastern Time, to discuss the Company,s,operating results for the ... operational update. Operating results for the quarter and year,ended ... that day., Stephen P. MacMillan, President and Chief ...
... of over 100 RNA-related Inventions a Key Step in Establishing ... MDRNA ... Nastech,Pharmaceutical Company Inc. ("Nastech") (Nasdaq: NSTK ) announced today ... and (ii) Nastech,s own intellectual property, as such intellectual,property relates ...
Cached Biology Technology:Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 2Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 3Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 4Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the World's Largest, Most-Advanced Automated Pharmacy 5Stryker to Host Conference Call on January 23, 2008 2Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc. 2Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc. 3Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc. 4Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc. 5
(Date:7/24/2014)... out of York University shows a surprisingly effective way ... fungus: moose saliva (yes moose saliva). , Published ... inhibits a grassendophyte mutualism" shows that moose and reindeer ... a fungus called epichlo festucae that produces the toxin ... , "Plants have evolved defense mechanisms to protect themselves, ...
(Date:7/24/2014)... The University of Texas Health Science Center at Houston ... help Harris County residents whose vision problems cannot be ... corrective lenses, many people with low vision can see ... low vision devices, such as telescopes, magnifiers and electronic ... is using the three-year, $164,645 SightFirst grant from the ...
(Date:7/24/2014)... in the United States, wildland managers often utilize the ... trees (ladder fuels). These cuttings and other post-logging ... danger in order to dispose of the material. To ... often cover all or part of the debris pile ... plastic, in order to keep water out. A recent ...
Breaking Biology News(10 mins):Moose drool inhibits growth of toxic fungus: York U research 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... WI, JANUARY 5, 2009 Currently, plant testing ... risks from chemical pesticides to nontarget plants requires ... Protection of the plant development and reproduction are ... of animals. Past research conducted by the USEPA ...
... UNDERSTANDING GENETIC AND SOCIOECONOMIC DIFFERENCES,CAREFREE, AZ,FEBRUARY 3-6, 2009 ... ethnic differences in treatment and outcomes among cancer ... the underlying causes and what can be done ... Association for Cancer Research is hosting a collaboration ...
... long suffered an identity crisis. Pop culture heedlessly ... dinosaurs. Even paleontologists assumed that because the creatures flew, they ... legs to take flight. Now comes ... 500 pounds of reptilian heft into flight required pterosaurs to ...
Cached Biology News:American Association for Cancer Research hosts Science of Health Care Disparities Meeting 2Four, three, two, one . . . pterosaurs have lift off 2
... I, ds Qualified is a special preparation of ... for double stranded cleavage of DNA molecules. In ... the enzyme makes double strand breaks at random ... resulting fragments can be controlled by the enzyme ...
... type 14 3C protease from human rhinovirus ... the Novagen brand line of restriction grade ... purified recombinant 6XHis-fusion protein, which recognizes the ... LeuGluValLeuPheGln/GlyPro. The small, 22 KDa size of ...
... Hybaid's unique Electro-4 design allows "4 gels ... it is possible to run 200,samples or ... stacking up to four,horizontal gels. To ensure ... to the number of gels being run. ...
... The IEC Centra CL3 series is ... typical research and clinical applications at ... accessory package includes quick connect rotors ... advanced yet intuitive interface allows you ...
Biology Products: